Gilead says remdesivir shows improvement in COVID-19 patients when used early

(Reuters) - Gilead Sciences Inc's experimental antiviral drug remdesivir helped improve symptoms in COVID-19 patients who were given the drug early than among those who were treated later, the company said.The closely-watched drug has moved markets in the past few weeks and on Wednesday broader markets once again rose on the data and Gilead shares also jumped 9%. In Gilead's study, 62% of patients treated early were discharged from the hospital, compared with 49% of patients who were treated..